Agios Pharmaceuticals has been granted a patent for compounds that activate pyruvate kinase R, represented by a specific formula. The patent includes pharmaceutical compositions and methods of use for these compounds. GlobalData’s report on Agios Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Agios Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Agios Pharmaceuticals's grant share as of May 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Activating compounds for pyruvate kinase r
A recently granted patent (Publication Number: US11957680B2) discloses a compound with a specific structural formula, along with its pharmaceutically acceptable salt, for use in pharmaceutical compositions. These compositions are intended for the treatment of conditions such as sickle cell disease, pyruvate kinase deficiency (PKD), and thalassemia in subjects. The patent also covers methods for administering the compound to address the mentioned conditions effectively.
Furthermore, the patent extends its scope to encompass treating various blood disorders like hereditary spherocytosis, hereditary elliptocytosis, anemia, and conditions affecting red blood cells. The methods outlined in the patent involve administering the compound or its salt to increase hemoglobin levels, prolong the lifespan of red blood cells, regulate 2,3-diphosphoglycerate levels in blood, and activate pyruvate kinase R (PKR) in red blood cells. These innovative methods aim to address a range of blood-related disorders and conditions in subjects in need of such treatments, showcasing the potential of the disclosed compound in the field of hematology and pharmaceutical interventions.
To know more about GlobalData’s detailed insights on Agios Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
